Global Information
회사소개 | 문의

브로모도메인 함유 단백질 2 : 파이프라인 리뷰

Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Pipeline Review, H1 2018

리서치사 Global Markets Direct
발행일 2018년 05월 상품 코드 516025
페이지 정보 영문 50 Pages
가격
US $ 3,500 ₩ 3,927,700 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 7,855,400 PDF by E-mail (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 11,783,100 PDF by E-mail (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


브로모도메인 함유 단백질 2 : 파이프라인 리뷰 Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Pipeline Review, H1 2018
발행일: 2018년 05월 페이지 정보 : 영문 50 Pages

한글목차

브로모도메인 함유 단백질 2(Bromodomain Containing Protein 2)를 표적으로 한 치료제 개발에 관한 정보를 제공하고, 개발 단계, 약제 표적, 작용기서, 투여 경로 및 분자 종류별 분석, 치료제 개발에 참여하고 있는 기업 개요, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

서론

  • 조사 범위

브로모도메인 함유 단백질 2 : 개요

브로모도메인 함유 단백질 2 : 치료제 개발

  • 개발중인 제품 : 개발 단계별
  • 개발중인 제품 : 치료 분야별
  • 개발중인 제품 : 증상별
  • 기업에서 개발중인 제품

치료제 평가

  • 작용기서별
  • 투여 경로별
  • 분자 종류별

치료제 개발에 참여하고 있는 기업

  • F. Hoffmann-La Roche Ltd
  • Forma Therapeutics Inc
  • Incyte Corp
  • Merck & Co Inc
  • Nuevolution AB
  • Resverlogix Corp
  • Trillium Therapeutics Inc

약제 프로파일

휴지중인 제품

개발이 중지된 제품

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

KSM 17.09.14

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

영문목차

Summary:

Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) pipeline Target constitutes close to 8 molecules. The latest report Bromodomain Containing Protein 2 - Pipeline Review, H1 2018, outlays comprehensive information on the Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Bromodomain-containing protein 2 is a protein that is encoded by the BRD2 gene. It plays a role in spermatogenesis. It plays a role in the regulation of transcription, probably by chromatin remodeling and also plays a role in nucleosome assembly. It regulates transcription of the CCND1 gene.

The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 2 and 3 respectively. Report covers products from therapy areas Oncology, Dermatology, Immunology and Respiratory which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Diffuse Large B-Cell Lymphoma, Multiple Myeloma (Kahler Disease), Atopic Dermatitis, Myelodysplastic Syndrome, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Colon Cancer, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Idiopathic Pulmonary Fibrosis, Inflammation, Lung Cancer, Malignant Pleural Mesothelioma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelofibrosis, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Solid Tumor, Systemic Lupus Erythematosus and Systemic Sclerosis (Scleroderma).

Furthermore, this report also reviews key players involved in Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2)
  • The report reviews Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Overview
  • Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Companies Involved in Therapeutics Development
  • F. Hoffmann-La Roche Ltd
  • Forma Therapeutics Inc
  • Mitsubishi Tanabe Pharma Corp
  • Nuevolution AB
  • Trillium Therapeutics Inc
  • Zenith Epigenetics Ltd
  • Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Drug Profiles
  • birabresib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CPI-0610 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FT-1101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NUE-19796 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NUE-7770 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RG-6146 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TTI-281 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ZEN-3694 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Dormant Products
  • Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Discontinued Products
  • Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Product Development Milestones
  • Featured News & Press Releases
  • Feb 09, 2018: Constellation Pharmaceuticals Announces Upcoming Presentations on its Anti-Cancer Drug Candidate CPI-0610
  • Nov 27, 2017: Nuevolution to Present New Data on its BET BD1 Program Supporting Effect in Psoriasis/Atopic Dermatitis
  • Oct 27, 2017: Nuevolution to present new data on its BET BD1 program supporting the understanding of the biological mode-of-action
  • Aug 24, 2017: Cancer Drug Can Reactivate HIV
  • Jul 05, 2017: Trillium Provides Update on Preclinical Development Program, TTI-281
  • Jun 19, 2017: Nuevolution Presents Additional Positive Animal Results in Lupus from its BET Selective Program
  • Jun 05, 2017: Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention
  • Dec 14, 2016: Zenith Announces Initiation of Phase 1b Clinical Combination Trial for ZEN-3694
  • Sep 16, 2016: Presentation of preclinical data on its BET BD1 program at Discovery on Target 2016
  • Jun 15, 2016: Zenith Announces Dosing of First Patient in Phase 1 Clinical Trial and Corporate Update Webcast Details
  • Jan 12, 2016: FORMA Therapeutics Enrolls First Patient in Phase 1 Study of FT-1101 in Advanced Hematological Malignancies
  • Mar 18, 2015: New Data Investigating Merck's MK-8628 in Advanced Non-Small Cell Lung Cancer and Mesothelioma to Be Presented in Clinical Trials Plenary Session at AACR 2015
  • Nov 12, 2014: Oncoethix Starts Phase 1b Trials of OTX015 in the Treatment of Advanced Solid Tumors (OTX015_107) and Glioma (OTX015_108)
  • Nov 20, 2013: Tensha Therapeutics Announces First Clinical Trial of BET Bromodomain Inhibitor TEN-010 for Treatment of Cancer
  • Sep 10, 2013: Constellation Pharmaceuticals Initiates Clinical Development of CPI-0610, a Novel BET Protein Bromodomain Inhibitor, in Patients with Lymphoma
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indications, H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
  • Pipeline by Forma Therapeutics Inc, H1 2018
  • Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018
  • Pipeline by Nuevolution AB, H1 2018
  • Pipeline by Trillium Therapeutics Inc, H1 2018
  • Pipeline by Zenith Epigenetics Ltd, H1 2018
  • Dormant Projects, H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
La Merie Publishing
BCC Research